A recent split decision by the U.S. Court of Appeals for the Federal Circuit illustrates the divisions in the court over the standards for preliminary injunctions as well as for patent invalidity based on obviousness.
On Jan. 9, the majority in Celsis In Vitro Inc. v. CellzDirect Inc. affirmed a preliminary injunction for Celsis against CellzDirect and Invitrogen Corp. issued by Judge Milton Shadur of the Northern District of Illinois. Life Technologies is the successor company to Invitrogen Corp. and CellzDirect’s parent company.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
